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Since the year 2000, the world elderly population increased by 48%. Medical problems become more 
predominant with aging leading to polypharmacy. Biological changes can
in increased susceptibility of older people to medications and their side effects. These changes may 
have greater effect in a frail person or person with number or long
conditions. Atorvastatin, rosu
medications among elderly. This paper has reviewed clinical trials and publications on these 
medications among elderly. It has been found that the 
among elderly had been evaluated with the main focus on the effectiveness of these medications on 
different medical conditions and less focus on the effects of the elderly pharmacokinetics and 
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Since the year 2000, the world elderly population increased by 
48% reaching 901, 000,000 in 2015. Considering the disparity 
of the definition of ‘elderly’ between developed
and developing countries (60 years old) this statistics were 
based on persons aged 60 years of age and over
people, medical problems become more predominant with 
aging leading to polypharmacy (1-3). In 2004, medication use 
by the elderly risen by 3-5 fold from the previous year and the 
authors expected that this trend will continue
persons are 2 fold likely to experience increase in medications 
effects and side effects than younger adults
cases the severity of the side effects will reduce adherence to 
therapy and quality of life and may lead to increased doctors’ 
visits and hospital admissions (6). For instance blood pressure 
medications decrease older people blood pressure
dramatically than younger adults (7). The high reduction in 
blood pressure can result in side effects including light
headedness, dizziness and falls which can further affect the 
older person quality of life or life if resulted in fractures or 
head injuries (7).  
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vastatin, perindopril, amlodipine and paracetamol are commonly used 
safety and effectiveness of these medicat
linical trials are required to test elderly 
effects on these medications. 
 article distributed under the Creative Commons Attribution 
the original work is properly cited. 
 (65 years old) 
 (1, 2). In most 
 (4). Older 






Biological changes can occur with aging resulting in increased 
susceptibility of older people to medications and their side 
effects (5). The function of different organ systems is 
decreased with aging at different rates. These changes are not 
enough to alter daily function in the case of healthy old person, 
but may have greater effect in a frail person or person with 
number or long-term or chronic diseases and conditions
Older people account for the most of coronary heart disease 
deaths sedentary lifestyle and dietary indiscretion to 
compensate for required effort 
led to high metabolic syndrome prevalence in older people 
such as obesity, high lipid levels and insulin resistance
Different large-scale studies demonstrated the association 
between high total cholesterol levels and 
disease among older people (9, 10
disagreed with this conclusion and suggested that the link 
between coronary artery disease and total cholesterol is 
diminished with aging (11, 12)
>= 65 years take >=1 medication every week and more than 
40% takes >= 5 medications (
aged >= 65 years take >= 10 medications
female takes more medications than male
frequently hospitalised, living in a nursing home or the frail 
receive the most medications 
nursing homes take a mean of 7
addition to over the counter medications
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The 2015 report of the Australian Bauru of Statistics on 
medicines highlighted the usage of medications among 
Australian population based on Pharmaceutical Benefits 
Scheme (PBS) and Repatriation Pharmaceutical Benefits 
Scheme (RPBS) information (14). The Australian Bauru of 
Statistics 2015 report divided the medications usage into 
different category including daily dose, prescription count and 
total cost (Table 1) (14). This paper will focus on the usage of 
five medications including atorvastatin, rosuvastatin, 
perindopril, amlodipine, paracetamol among elderly 
population. 
 
MATERIALS AND METHODS 
 
A search of the literature was conducted through Google™ 
Scholar, Medline™ and PubMed databases to identify studies 
in English language. The following keywords andterms were 
used:<Aging and drugs>, <medication usage among 
elderly>,<elderly elderly physiological changes>, <atorvastatin 
clinical trials AND elderly>, <rosuvastatin clinical trials AND 
elderly>, <perindopril clinical trials AND elderly>, 
<amlodipine clinical trials AND elderly>,<paracetamol 
clinical trials AND elderly>.Letters, commercial websites and 
commentaries were excluded, only informational websites and 
peer reviewed articles were included (Appendix 1). 
 
RESULTS AND DISCUSSION 
 
Statins: Several prospective randomized clinical trials 
demonstrated statins effectiveness in reducing major coronary 
incidents (15-18).  
 
Table 1. Top 10 medications based on different category, based on 
the Australian Bauru of Statistics report, 2015 (14) 
 






















METFORMIN HYDROCHLORIDE 5,155,883 
AMOXYCILLIN with CLAVULANIC ACID 5,067,228 
3.Top 10 drugs by total cost 2015 
Drug Total Cost 













Figure 1. Atorvastatin, rosuvastatin, perindopril, amlodipine and 




Figure 2. Clinical trials consideration of elderly  
physiological changes 
 
However, the early trials lack adequate representation of the 
elderly patients (19) as a result the American Heart 
Association (AHA) has urged doctors to provide further 
evidence for statin treatment among the elderly (20). Adverse 
events have been a concern in the elderly patients (21) due to 
seriousness of side-effects versus the possible immediate or 
short-term benefit (21-24). Many studies propose that statins 
underutilized among elderly patients in cardiovascular disease 
primary and secondary preventions, have its established 
benefits (25, 26). This has been ascertained in the data from 
the Global Registry of Acute Coronary Events (GRACE) and 
the National Registry of Myocardial Infarction (12, 27, 28). 
Heart Protection Study (HPS), which recruited 9839 
participants under the age of 65 years, 4891 participants aged 
between 65and70 years, and 5806 participants aged 70 years 
and over, indicated that that the relative reduction was similar 
in incident rates across different age groups (29).  
 
Atorvastatin: Atorvastatin has been extensively studied 
among the elderly and shown to have positive effects on CHD 
clinical outcomes (12). The ‘Assessing Goals in the Elderly’ 
(SAGE) study examined intensified statin treatment in 
893CHD elderly patients aged between 65–85 years (17) who 
were diagnosed with stable CHD (LDL-C between 100-250 
mg/dL, had ≥ 1 ischaemic event at baseline). Participants were 
monitored using 48-hours ambulatory ST segment ECG 
monitoring (17). Pravastatin 40 mg/day or atorvastatin 80 
mg/day were assigned randomly to the participants who were 
followed-up for 12 months. The results showed that patients 
who were treated with pravastatin - had a significant reduction 
in LDL-C when compared with those treated with atorvastatin, 
(32% vs55% at 12 months), total cholesterol, apolipoprotein B 
and triglycerides at both3 and 12 months (p < 0.001 for all).  
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Both medications demonstrated a significant and equal 
reduction in the number and duration of episodes of chest pain 
(where an event marker button is pressed at the onset of 
symptoms on ambulatory ECG monitor) compared to baseline 
(17). It had been noted that all-cause mortality was reduced by 
77% (1.3 vs 4%, hazard ratio [HR] 0.33, 95% confidence 
interval [CI] 0.13–0.83, p = 0.014) and acute cardiovascular 
cases trend were fewer (8.1 vs 11.2%, HR 0.71, 95% CI 0.46–
1.09, p = 0.114) with atorvastatin compared to pravastatin at 
12 months. A secondary investigation of the ‘Treating to New 
Targets’ (TNT) trial showed a 19% relative risk reduction in 
major cardiovascular cases in participants aged 65 years and 
over (3809patients) who receivedhigh-dose atorvastatin (30). 
Patients received intensified atorvastatin treatment (all ages) 
showed similar absolute risk decline by2.3%. Moreover, 
elderly participants who received atorvastatin 80 mg daily had 
lower CHD death, nonfatal or fatal strokes and nonfatal non-
procedure-associated MI rates however, this reduction was not 
deemed to be of statistical significance (30). Also, this study 
suggested that high-risk older participants with existing CHD 
could benefit from the treatment as it could offer clinical 
advantage (12, 30).  
 
Another study “The Incremental Decrease in End points 
through Aggressive Lipid lowering (IDEAL) ” recruited 8888 
participants aged less or equal to 80 years who suffered acute 
MI, showed participants who received atorvastatin experienced 
considerably lower mean levels of total triglycerides and 
cholesterol and LDL-C, after 4.8 years average follow-up 
when compared with participants who received simvastatin 
(31). The primary outcome (defined as time to first occurrence 
of a major coronary event) was not considerably decreased 
with atorvastatin treatment (31). However, there were 
considerable rates decrease of major cardiovascular cases and 
acute nonfatal MI. the study did not publish separate data 
regarding elderly participants in the trial, but the authors’ 
preliminary analysis did not show any statistically considerable 
treatment group interference by age (12, 31). In another study, 
the effects of pravastatin 40 mg daily (standard dose) and 
atorvastatin 80 mg daily (intensified dose), in 4162 participants 
was evaluated (32).  
 
The results revealed that atorvastatin group showed greater 
reduction in their average LDL-C than pravastatin group and 
median LDL-C was led for atorvastatin than with pravastatin. 
The main end point (defined as the death from any reason 
including unstable angina which required rehospitalisation e.g., 
MI, stroke and revascularization) was decreased by 16% in the 
atorvastatin group compared to pravastatin group. The benefit 
from atorvastatin was evidentas early as 30 days after 
treatment commencement and was steady over time (32). Ray 
et al., (2007) in a post-hoc analysis of patients aged 70 years 
old data, showed a higher percentage of participants reached 
the LDL-C targets at thirty days in the atorvastatin 80 mg daily 
group compared to participants of the same age in the 
pravastatin 40 mg daily group (p < 0.001,74.6% versus 
27.7%,) (33). The achievement of LDL-C target of <70 mg/dL 
and maintenance for two years, resulted ina 40% lower death 
risk and unstable angina or MI events when compared to 
participants who did not reach the target or maintained it. In 
the Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering (MIRACL) trial, (n=3086 participants, 
1672 >65 years), participants were assigned randomly to either 
placebo or atorvastatin 80 mg daily for 16 weeks, 24-96 hours 
after hospital admissiondue to ACS (34).  
Olsson et al., (2007) defined primary end point as (nonfatal 
acute myocardial infarction, resuscitated cardiac arrest, 
recurrent symptomatic myocardial ischemia with objective 
evidence requiring rehospitalization) ) Secondary end points 
were the occurrence of individual components of the primary 
end point and the occurrence of nonfatal stroke, new or 
worsening congestive heart failure requiring hospitalization, 
worsening angina requiring hospitalization but without new 
objective evidence of ischemia, coronary revascularization, 
time to occurrence of any of the secondary end points, and 
percent changes in lipid levels from baseline to end of study. 
Olsson et al., (2007) (concluded that the primary end 
pointrelative reductions in LDL-C were similar in older and 
younger patients who were treated with atorvastatin (14% 
versus 22%, p = 0.62). Additionally, 34 of the elderly 
participants were needed to be treated compared to 40 younger 
participants (35). In the 80 years old group, received 
atorvastatin, 34% reduction in the LDL-C was achieved 
compared to participants in placebo group (35). The treatment 
effects were the same between older and younger groups of 
each primary and secondary end point components (35).  
 
Age and gender effects on atorvastatin pharmacokinetics 
followed one 20mg tablets dosing were examined in 16 elderly 
(66–92 years old) and 16 young (19–35 years old) participants 
(36). Both groups composed of 50% women and 50% men. A 
validated enzyme inhibition bioassay was used to quantify 
atorvastatin plasma equivalent concentrations (36). All 
participants tolerated atorvastatin well (36). Elderly 
participants showed 42.5% higher equivalent maximum 
concentration (Cmax) than young participants (36). Cmax was 
17.6% lower in men than in women. Additionally, the half life 
(t1/2) and the mean area under the concentrationtime curve 
(AUC0‐ ∞) were 36.2% longer and 27.3% greater, respectively, 
in elderly participants than in young participants and 11.3% 
higher and 19.9% longer, respectively, in men than in women 
(36). The study stated that it is unclear whether gender- and 
age related changes in atorvastatin pharmacokinetics will be 
clinically important and whether they would affect atorvastatin 
extensive first pass hepatic metabolism. Thus, more trials are 
required to ensure atorvastatin efficacy and safety among 
different age and gender groups (36).  
 
Summary of findings: Based on the reviewed studies, 
atorvastatin shown that while the reduction in LDL-C is better 
than pravastatin it is less effective in reducing total cholesterol, 
apo-lipoprotein B and triglycerides. Moreover, atorvastatin 
showed significant reduction in the number and duration of 
episodes of chest pain, all-cause mortality and acute 
cardiovascular cases trend. High-dose atorvastatin showed to 
lower relative risk in major cardiovascular cases, CHD death, 
nonfatal or fatal strokes and nonfatal non-procedure-associated 
MI. The benefit from atorvastatin was evident as early as 30 
days after treatment commencement and was steady over time. 
Elderly participants showed 42.5% higher equivalent 
maximum concentration (Cmax) than young participants, the 
half life (t1/2) was longer and the mean AUC0‐ ∞was greater.  
 
Rosuvastatin: The a placebo-controlled, double-blind, 
randomized multi-centre Justification for the Use of Statins in 
Primary Prevention: an Intervention Trial Evaluating 
Rosuvastatin JUPITER study, (n=17,802 participants aged ≥50 
years for men and ≥60 years for women), participants were 
randomly assigned to receive either placebo or rosuvastatin 20 
mg/day (37). JUPITER study was stopped after 1.9 years 
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average follow-up because of the reduction in the arterial 
revascularization, stroke, myocardial infarction, unstable 
angina hospitalization, or death due to cardiovascular reasons 
were evident. Primary endpoint was statistically significant in 
rosuvastatin participants compared to participants in the 
placebo group (37). The subgroups’ results in rosuvastatin 
participants with similar noted reduction in relative hazard 
showed lack of evidence for heterogeneity based on gender, 
age (>65 and ≤65 years), ethnic or race group, place of origin, 
status regarding traditional risk and Framingham Risk Score 
(FRS) (37). Glynn et al., (2010) evaluated the safety and 
efficacy of rosuvastatin in 5695 participants aged >70 at 
baseline (38). The elderly group (23% of total participants) 
accounted for 49% of the total 393 who reached the primary 
endpoints (The primary end point was the occurrence of a first 
cardiovascular event (myocardial infarction, stroke, arterial 
revascularization, hospitalization for unstable angina, or death 
from cardiovascular causes). However, it was noted that the 
elderly participants had different other cardio-vascular risk 
factors profile to the younger subjects. The older subjects had 
higher percentages of participants with hypertension and 
women, and lower percentages of cigarette smoking and 
obesity than the younger participants (38). Also, the study 
results illustrated that in the rosuvastatin participants theHigh 
Sensitivity C-Reactive Protein (hsCRP) levels and lipid levels 
were reduced similarly in both the younger and the elderly 
groups (38).  
 
The rosuvastatin participants’ averageLDL-C levels were half 
those in both age groups who received placebo. Also, It was 
noted in both age groups that the average hsCRP levels were 
about 36% less in the rosuvastatin participants compared to the 
placebo group (38). The JUPITER participants aged >70 years 
showed primary endpoint (The primary end point was the 
occurrence of a first cardiovascular event (myocardial 
infarction, stroke, arterial revascularization, hospitalization for 
unstable angina, or death from cardiovascular causes) rates of 
1.99 and 1.22 per 100 person-years of follow-up in the placebo 
and rosuvastatin groups, respectively (38). The relative 
risk reduction (RRR) is slightly more uncertain among the 
elderly participants than younger participants aged between 50 
and 69 years. Furthermore, the primary endpoint events 
absolute reduction was 48% greater among elderly participants 
than younger participants when combined with the fact that old 
people had more cardiovascular events rate JUPITER study 
illustrated that the adverse events rates were higher among the 
older participants than younger participants, however, 
rosuvastatin group did not show additional side effects than 
those presented in the placebo group. JUPITER study has been 
recognized to have several limitations of its overall design 
(39). This includes the possibility that benefits might be 
exaggerated due to the early trial termination (40). However, 
the USA Food and Drug Administration’s independent review 
concluded that any the RR reduction potential over estimation 
because of early termination would be negligible and not alter 
the overall trial findings (41). It has been stated that the elderly 
aged >= 65years and young populations don’t show different 
rosuvastatin plasma concentrations (42). Cytochrome P450 
2C9 mainly metabolises rosuvastatin to N-desmethyl 
rosuvastatin, the main metabolite (42). The time to reach 
rosuvastatin peak plasma concentrations is between 3-5 hours 
after oral dosing and its elimination half-life (t1/2) is nearly 19 
hours (42). 28% and 72% of rosuvastatin total body clearance 
is cleared renally and hepatically respectively after 
administering rosuvastatin intravenously (42).  
Moreover, as rosuvastatin dose increases the area under the 
plasma concentration-time curve (AUC) and peak 
concentration (Cmax) increase in approximate amount (42, 
43). Rosuvastatin absolute bioavailability is nearly 20% (42). 
20% decrease in rate of rosuvastatin absorption was noted if it 
was administered with food based on Cmax value,but the 
extent of absorption was not affected based on AUC value 
(42). Additionally, morning or evening rosuvastatin 
administration showed same plasma concentrations (42). 
Eighty eight percent of rosuvastatin bounds to plasma proteins, 
mainly albumin which is independent and reversible of plasma 
concentrations (42).  
 
Summary of findings: Based on the reviewed literature 
rosuvastatin had shown to reduce the arterial revascularization, 
stroke, myocardial infarction, unstable angina hospitalization, 
or death due to cardiovascular reasons. Also, rosuvastatin 
reduced the average LDL-C levels, the hsCRP levels and the 
occurrence of a first cardiovascular event had reduced more 
significantly among the elderly who received rosuvastatin than 
younger people. However, the adverse events rates were higher 
among the older than younger people but no differencein 
plasma concentrations. 
  
Perindopril: Perindopril safetyand effectiveness among 
elderly had been evaluated in a large USA trial of 3010 
participants aged 65 years and over (44). The study showed 
that treatment with perindopril as a monotherapy resulted in 
blood pressure reduction in both young and elderly participants 
diagnosed with hypertension. Only 51.9% and 41.4% of young 
and elderly participants respectively achieved target blood 
pressure of <130/80 mm Hg when taking perindopril as a 
monotherapy to control hypertension (44). The study indicated 
that hypertensive elderly participants did not respond to 4mg 
daily dose adequately. Increasing daily dose to 8mg improved 
blood pressure reduction in both elderly and young participants 
(44). At week-12, the 8mg daily dose improved blood pressure 
control by nearly 5-fold in both age groups (44). The blood 
pressure target of 130/80 mmHg (primary endpoint) achieved 
by 15.6% of patients diagnosed with both diabetes and 
hypertension when taking perindopril monotherapy (44). 
Moreover, the study found that perindopril was well tolerated, 
safe and effective in reducing blood pressure in all elderly 
participants’, aged >75 years (44). Cough incidence was 
established in both elderly and young participants (7-10%) and 
postural hypotension incidence was low (less or equal to 
0.2%). These results support the safety profile and tolerance of 
perindopril (44). A meta-analysis showed a significant 
reduction in the number of patients reaching primary endpoint 
when they administered perindopril compared with all other 
ACEIs (29). A randomized, double-blind, parallel-group, 
placebo-controlled, multi-centre study evaluated perindopril 
effects on heart remodelling as well as clinical outcome among 
elderly aged >=65 years cardiac patients (45). The study 
recruited 1252 participants (with >=40% ejection fraction of 
the left ventricle and current acute MI) who were assigned to 
either placebo or perindopril erbumine 8mg daily dose for 12 
months (45). The study found that after one year of treatment 
with perindopril 8mg per day, progressive remodelling of the 
left ventricle was reduced but clinical outcomes did not change 
or improve (45). Another double-blind randomized study 
evaluated the usage of perindopril 4mg per day versus placebo 
in 850 participants aged >70 years who are diagnosed with 
heart failure and currently taking diuretics, found that 
hospitalisation due to heart failure complications (a 
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combination of unplanned heart failure associated with 
hospitalisation and all-cause mortality death) were reduced in 
perindopril group after one year treatment (31). Also, 
perindopril group showed improvement in the walking 
distance and functional class after one year (31).  
 
A crossover, double blind, acute study examined the effect of 
age on the pharmacodynamics and pharmacokinetics of 
angiotensin converting enzyme inhibitor “S 9780” and 
perindopril (which is S-9780 ester prodrug). One milligran 
S 9780 was administered intravenously and eight milligram 
perindopril was administered orally. The study conducted in 8 
young (aged 29 ± 3 years) and 8 elderly (aged 71 ± 3 years) 
healthy participants. The younger participants suffered only 
from mild light headedness and headache which are more 
common among them compared with the elderly participants 
who suffered from higher blood pressure fall rate (35% ± 17% 
vs 19% ± 7%; p < 0.025). S 9780 bioavailability was greater 
among elderly participants due to greater conversion rather 
than absorption. S 9780 renal clearance was greater in the 
young participants than in the elderly (110 ± 39 ml/ min vs 67 
±31 ml/min ; p < 0.03). Thus, the study suggested an 
approximate 50% dose reduction for elderly patients with 
consideration to any pre-existing reduced renal function which 
might require further adjustment (46).  
 
Summary of findings: It has been found from the reviewed 
studies that perindopril was well tolerated, safe and effective in 
reducing blood pressure in all elderly people including those 
aged >75 years. Studies show that increasing daily dose to 8mg 
improved blood pressure reduction in both elderly and young 
people.Perindopril bioavailability was greater among elderly 
participants due to greater conversion rather than absorption. 
However, renal clearance was greater in the young than in the 
elderly people. Thus, it has been suggested an approximate 
50% dose reduction for elderly patients with consideration to 
any pre-existing reduced renal function which might require 
further adjustment. 
 
Amlodipine: A study conducted among elderly diagnosed 
with hypertension aged between 65 and73 years and 
youngerparticipants aged between 28 and 34 year who were 
given IV amlodipine followed by oral amlodipine once daily 
for two weeks, found that the elderly participants had a 
reduced amlodipine clearance compared with the young 
participants after the IV infusion. This prolongation of 
amlodipine half-life resulted in greater reduction in systolic 
and diastolic blood pressure compared to young participants. 
After fourteen weeks treatment, systolic blood pressurewas 
significantly reduced in the elderly group, while diastolic 
blood pressure was reduced at two and fourteen weeks 
treatment (47).  
 
A USA large recent community-based trial showed that 
amlodipine was more effective among elderly participants 
when compared to younger than 65 years (48). Also, other 
studies found that majority of participants tolerated amlodipine 
at good or excellent levels (49, 50). Furthermore, it has been 
illustrated that amlodipine tendency to cause vasodilatory 
adverse-effects was reduced due to its slow absorption nature 
when it was given orally. Another study showed that the 
circadian rhythms of blood pressure were not altered among 
participants whose blood pressure was controlled by a 24 hours 
amlodipine dosage (51). Moreover, the heart dimension was 
decreased (51).  
Furthermore, 75% of the participants (elderly) had normal 
blood pressure after treatment with amlodipine as a 
monotherapy (51). Another study concluded that low dose 
amlodipine per day were efficacious and well tolerated by 
elderly with hypertension (52). The study illustrated that 
diastolic and systolic blood pressure readings were decreased 
at weeks 8 (153 +/- 17, 90 +/- 9 mmHg) and 12 (152 +/- 16, 90 
+/- 9 mmHg) when compared with week 0 (164 +/- 16, 99 +/- 
6 mmHg) and 16 (162 +/- 19, 95 +/- 9 mmHg) (52). It has been 
documented that amlodipine pharmacokinetics are not altered 
significantly in elderly or patients with renal impairment (53). 
However, hepatically impaired patients showed reduced 
clearance rates (53). Amlodipine absorption is slow when 
administered orally (53). The peak plasma concentration 
reached 6-12 h after dose and the absolute bioavailability is 60-
80% (53, 54). Amlodipine has an extended elimination half-
life (t1/2) (40-60 h) (54) due its great volume of distribution 
and low clearance rate (53). Additionally, amlodipine once 
daily dosing is sufficient to maintain mean effective plasma 
concentrations (53). Amlodipine steady state is reached after 
7th-9th dose when administered once daily (53). The sharp 
fluctuations in plasma concentration (that are resulted from 
vasodilatation-induced adverse effects such as flushing, 
tachycardia and headache) were not seen in amlodipine 
pharmacokinetic properties compared with other calcium 
antagonists (53). Blood pressure is reduced slowly over 4h to 
8h followed single doses and may gradually reaches baseline 
again over 24h to 72 h (54). It has been noted that the heart 
rate has not been changed followed the dose due to the gradual 
onset hence physiological reflexes are not stimulated (54). 
Additionally, baseline blood pressure is returned gradually 
over 7 to10 days followed amlodipine treatment 
discontinuation with no ‘rebound’ effect indication (54).  
 
Summary of findings: It had been found in the reviewed 
literature that the elderly had a reduced amlodipine clearance 
resulting in the prolongation of the half-life and greater 
reduction in systolic and diastolic blood pressure compared to 
young people. Also, amlodipine was found to cause reduced 
vasodilatory adverse-effects due to its slow absorption nature 
when it was given orally. It has been documented that 
amlodipine pharmacokinetics were not altered significantly in 
elderly.  
 
Paracetamol: Paracetamol oral bioavailability (F) has been 
investigated in number of studies. One study found that F in 
older participants was similar to F of young participants (55). 
More than one study showed that young participants tended to 
have a higher F of both elixir and tablets than older 
participants (56, 57). However, clinical relevance was not 
significant (56). Furthermore, F remained the same in all other 
age groups (57). Three studies found that there was no 
significant difference in half-life and lag time (tlag) between 
different age groups (56, 58, 59). Older participants showed 
longer absorption time when taken paracetamol elixir with 
food than younger participants. Caution should be considered 
when applying these results in clinical practicedue to the great 
inter-individual differences regardless of age (57). The 
difference of the extent and the rate of absorption between 
different age groups were not clinically significant. Moreover, 
theabsence of older frail participants from these studies makes 
their results not conclusive to all age group. Volume of 
distribution (Vd) might be influenced by age. It has been 
shown that older participants had relatively lower Vd than 
younger participants (60). The decreased Vd with age is 
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potentially due to the paracetamol relative hydrophilic nature 
and the high fat portion among older persons compared to 
younger persons, consequently increasing plasma 
concentration of paracetamol among older persons (61).  
 
Another study illustrated that health condition can potentially 
affect pharmacokinetics. Frail older participants showed lower 
Vd than young and robust older participants (60). This result 
has been supported in Ellmers et al., (1991) study which 
showed lower Vd among frail older participants than robust 
older persons. More than one study demonstrated that robust 
older women had smaller Vd than older robust men which is 
potentially due the fact that women’s total body weight 
composed of larger amount of fat than men (62-64). More than 
one study (63-66) investigated sex-related differences in 
pharmacokinetic parameters between robust male and female 
older adults, of which four studies reported a smaller Vd in 
women compared with men (p < 0.05), ranging from 8.5 to 
17.5% (62-64). This is probably caused by the larger 
proportion of fat in a woman’s total body weight.It is 
reasonable to state that Vd decreases with increasing age, most 
pronouncedly in frail older people. Changes in Vd determine 
the influence of the loading dose, and the elimination half-life. 
Both statistical and clinical significance are still unknown.It 
has been shown in more than one trial that paracetamol 
clearance is reduced among robust older participants compared 
to younger participants (1).  
 
However, Triggs et al., (1975) and Miners et al., (1988) 
showed no substantial differences between different aged 
group (67, 68). Another study, comparing paracetamol CL on 
days 1 and 7 during repeated administration, reported no 
paracetamol accumulation. However, this does not imply 
anything regarding possible accumulation of the (toxic) 
metabolites.Additional factors besides age, such as disease, 
concomitant medication or general physical status (e.g. frailty), 
may influence paracetamol metabolism. One study showed a 
26.4% decrease in the clearance (calculated using body 
weight) of paracetamol among frail participants compared with 
older robust older participants (1). However, the results differ 
when clearance was calculated using liver unit volume. Frail 
participants’ clearance rate reduced significantly by 32.9 and 
37.5 % when compared with robust older and young cases, 
respectively, but there is no significant difference between 
robust older and young participants (60). When CL was 
expressed per unit volume of liver, no significant differences 
were found between young and robust older participants, but it 
was significantly reduced in the frail participants. These results 
demonstrate that disease state and/or frailty can play a role in 
reducing clearance (60).  
 
Hepatotoxicity, gastrointestinal toxicity and nephrotoxicity 
have reported as possible side effects associated with 
paracetamol usage among elderly in seven studies (69-75). 
Mitchell et al., (2011) study indicated that the concentrations 
of alanine aminotransferase (ALAT) were the highest among 
younger participants when compared with robust older and 
frail older participants who were slightly above and within 
reference range, respectively (69). Another study conducted by 
Jahr et al., (2012) found that the liver enzyme did not differ 
significantly between participants65years old or more in 
placebo and paracetamol groups (70). Two studies stated that 
paracetamol usage showed no significant differences in 
between controls and hospitalised participants with duodenal 
ulcer or gastrointestinal bleeding (71, 73).  
However, Rahme et al., (2002) reported that participants who 
administered lower paracetamol dose were less likely to suffer 
gastrointestinal event when compared with participants who 
administered higher paracetamol dose (75). Creatinine 
clearance showed no significant reduction in the placebo and 
paracetamol groups in Koppert et al., (2006) study (72). 
Additionally, α-1-microglobulin, urine albumin, potassium and 
sodium showed a slight not significant increase (72).  
 
Summary of findings: Studies reviewed showed different 
opinion on the bioavailability of paracetamol changes in older 
people. The elderly showed longer absorption time when taken 
paracetamol elixir than younger people and relatively lower 
Vd than younger participants. It had been noted that disease 
state and/or frailty can play a role in reducing 
clearance.Hepatotoxicity, gastrointestinal toxicity and 
nephrotoxicity have reported as possible side effects associated 
with paracetamol usage among elderly in several studies.  
 
Statistical summary: Out of the 29 studies reviewed older 
people had been the main focus of 16 (55%) studiesonly but 
they were included in12 studies (Figure 1).  
 
The effect of age-related biologic and physiological 
(pharmacokinetic and pharmacodynamics) changes among 
elderly on drug dosageand selection had been either studied or 
not in different studies. As shown in figure 2, ninteen studies 
did not discuss the effects of elderly physiological changes on 
medications. Most of these papers included elderly with 
different medical conditions and studied the effectiveness of 
different drugs (atorvastatin, rosuvastatin, perindopril, 
amlodipine and paracetamol) on specific medical conditions 
(19 papers out 30, 63%). However, only eleven studies 
discussed elderly physiological (pharmacokinetic and 




It is apparent that the main focus of the most clinical trial was 
testing medications’ (atorvastatin, rosuvastatin, perindopril, 
amlodipine and paracetamol) effectiveness on different medical 
conditions with less focus on the effect of the elderly 
pharmacokinetic and pharmacodynamics changes on these 
medications and in many cases just predict the age effect rather 
than the actual effect. Thus, more clinical trials should focuson 
the effects of the age-related biological changes on medications 
which potentially can play a role in reducing medications’ side 
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Age Consideration When Prescribing for the Elderly  
Reference Type of study Sample 
size 





Conclusion drawn from the study 
Atorvastatin 
Deedwania P, Stone PH, 
Bairey Merz CN, Cosin-
Aguilar J, Koylan N, Luo D, 
et al. Effects of intensive 
versus moderate lipid-
lowering therapy on 
myocardial ischemia in 
older patients with coronary 
heart disease: results of the 
Study Assessing Goals in 
the Elderly (SAGE). 
Circulation. 2007 Feb 
13;115(6):700-7. PubMed 
PMID: 17283260. Epub 
2007/02/07. eng. 
Subjects were randomized to 
atorvastatin 80 mg/d or 
pravastatin 40 mg/d and 
followed up for 12 months.  
893  Compared with moderate 
pravastatin therapy, intensive 
atorvastatin therapy was 
associated with reductions in 
cholesterol, major acute 
cardiovascular events, and 
death in addition to the 
reductions in ischemia 
observed with both therapies.  
No Yes The contrast between the therapies' differing 
efficacy for major acute cardiovascular events and 
death and their nonsignificant difference in 
efficacy for reduction of ischemia suggests that 
low-density lipoprotein cholesterol-lowering 
thresholds for ischemia and major acute 
cardiovascular events may differ. The Study 
Assessing Goals in the Elderly (SAGE) 
demonstrates that older men and women with 
coronary artery disease benefit from intensive 
statin therapy. 
Colhoun HM, Betteridge 
DJ, Durrington PN, Hitman 
GA, Neil HA, Livingstone 
SJ, et al. Primary prevention 
of cardiovascular disease 
with atorvastatin in type 2 
diabetes in the Collaborative 
Atorvastatin Diabetes Study 
(CARDS): multicentre 
randomised placebo-
controlled trial. Lancet 
(London, England). 2004 
Aug 21-27;364(9435):685-
96. PubMed PMID: 
15325833. Epub 
2004/08/25. eng. 
Patients were randomised to 
placebo (n=1410) or atorvastatin 








2838 Atorvastatin 10 mg daily is 
safe and efficacious in 
reducing the risk of first 
cardiovascular disease 
events, including stroke, in 
patients with type 2 diabetes 
without high LDL-
cholesterol. No justification 
is available for having a 
particular threshold level of 
LDL-cholesterol as the sole 
arbiter of which patients with 
type 2 diabetes should 
receive statins. 
No Yes The debate about whether all people with this 
disorder warrant statin treatment should now focus 
on whether any patients are at sufficiently low risk 
for this treatment to be withheld. 
benefits of statin therapy far outweigh any safety 
concerns, especially among older CHD patients 
who may be otherwise healthy. By reducing 
morbidity related to acute coronary events, statins 
can enhance the quality of life and lead to a more 
productive old age. While extra caution is 
warranted with high-dose statin therapy, 
particularly in those with concomitant medical 
conditions such as chronic kidney or liver disease, 
increased chronological age alone should not 
exclude any patient from receiving the benefits of 
such treatment. Atorvastatin has been proven to 
improve clinical outcomes, even when compared 
to other statins in large randomized clinical trials, 
and is generally well tolerated in the elderly 
population. It is therefore a suitable choice when 
considering statin therapy in this group of patients 







Colhoun HM, Betteridge DJ, Durrington 
PN, Hitman GA, Neil HA, Livingstone 
SJ, et al. Primary prevention of 
cardiovascular disease with atorvastatin in 
type 2 diabetes in the Collaborative 
Atorvastatin Diabetes Study (CARDS): 
multicentre randomised placebo-
controlled trial. Lancet (London, 
England). 2004 Aug 21-
27;364(9435):685-96. PubMed PMID: 
15325833. Epub 2004/08/25. eng. 
Patients were randomised to placebo (n=1410) or 








2838 Atorvastatin 10 mg daily is safe and efficacious in 
reducing the risk of first cardiovascular disease 
events, including stroke, in patients with type 2 
diabetes without high LDL-cholesterol. No 
justification is available for having a particular 
threshold level of LDL-cholesterol as the sole 
arbiter of which patients with type 2 diabetes 
should receive statins. 
No Yes The debate about whether all people with this 
disorder warrant statin treatment should now 
focus on whether any patients are at sufficiently 
low risk for this treatment to be withheld. 
benefits of statin therapy far outweigh any safety 
concerns, especially among older CHD patients 
who may be otherwise healthy. By reducing 
morbidity related to acute coronary events, statins 
can enhance the quality of life and lead to a more 
productive old age. While extra caution is 
warranted with high-dose statin therapy, 
particularly in those with concomitant medical 
conditions such as chronic kidney or liver disease, 
increased chronological age alone should not 
exclude any patient from receiving the benefits of 
such treatment. Atorvastatin has been proven to 
improve clinical outcomes, even when compared 
to other statins in large randomized clinical trials, 
and is generally well tolerated in the elderly 
population. It is therefore a suitable choice when 
considering statin therapy in this group of patients 
Cournot M, Cambou JP, Quentzel S, 
Danchin N. Key factors associated with 
the under-prescription of statins in elderly 
coronary heart disease patients: Results 
from the ELIAGE and ELICOEUR 
surveys. International journal of 
cardiology. 2006 Jul 28;111(1):12-8. 
PubMed PMID: 16046011. Epub 
2005/07/28. eng. 
. Two cross-sectional pharmaco-epidemiological surveys 
were carried out among French cardiologists.  Patients' risk 
factors, medical history, treatments, lipid values and the 
physicians' various motives for the non-prescription of 
statins were recorded. Patients not treated with statins 
reached 37% in the age-group > or =70 years and 14% in the 
age-group 35-69 years. The main reason given for statin 
non-prescription was the lack of a medical indication (2.5% 
of the age-group 35-69 years and 14% of the age-group > or 
=70 years). Among patients > or =70 years, the lack of 
indication was more often cited in the following conditions: 
1) in very old patients (36% of lack of indication in the age-
group >85 years vs. 10% in 70-75 years), 2) when lipid 
values were not available (20% when data were not 
available vs. 9%) and 3) when the patient had no prior 
history of myocardial infarction (MI) (20% when no history 
of MI vs. 7%). These factors were not associated with lack 
of indication among patients <70 years. History of 
intolerance or side effect was given for 1.3% and 14% of 
patients for each of the groups (35-69 and > or =70) and 
poor overall patient adherence was cited in 1% and 2%, 
respectively. The primary reason for the under-prescription 
of statins in elderly coronary patients is the perceived lack 
of indication, which stresses the need of extensive 
guidelines for prescription in elderly patients. Several 
factors associated with this perception seem to be specific to 
the elderly. 
1148 coronary patients 
aged 35 to 69 years and 
1489 patients aged > or 
=70 years. 
Patients not treated with statins reached 37% in the 
age-group > or =70 years and 14% in the age-group 
35-69 years. The main reason given for statin non-
prescription was the lack of a medical indication 
(2.5% of the age-group 35-69 years and 14% of the 
age-group > or =70 years). Among patients > or 
=70 years, the lack of indication was more often 
cited in the following conditions: 1) in very old 
patients (36% of lack of indication in the age-group 
>85 years vs. 10% in 70-75 years), 2) when lipid 
values were not available (20% when data were not 
available vs. 9%) and 3) when the patient had no 
prior history of myocardial infarction (MI) (20% 
when no history of MI vs. 7%). These factors were 
not associated with lack of indication among 
patients <70 years. History of intolerance or side 
effect was given for 1.3% and 14% of patients for 
each of the groups (35-69 and > or =70) and poor 
overall patient adherence was cited in 1% and 2%, 
respectively.  
No Yes The primary reason for the under-prescription of 
statins in elderly coronary patients is the 
perceived lack of indication, which stresses the 
need of extensive guidelines for prescription in 
elderly patients. Several factors associated with 











Benner JS, Pollack MF, Smith TW, 
Bullano MF, Willey VJ, Williams SA. 
Association between short-term 
effectiveness of statins and long-term 
adherence to lipid-lowering therapy. 
American journal of health-system 
pharmacy : AJHP : official journal of 
the American Society of Health-
System Pharmacists. 2005 Jul 
15;62(14):1468-75. PubMed PMID: 
15998926. Epub 2005/07/07. eng. 
A retrospective cohort study was conducted among 
enrollees in a Southeastern managed care plan who 
started therapy with atorvastatin, fluvastatin, 
lovastatin, pravastatin, or simvastatin between October 
1999 and August 2001, were enrolled for > or =12 
months before and > or =6 months after treatment 
initiation, and had at least one LDL cholesterol 
measurement in the year before and 4-12 weeks after 
the start of therapy. Patients were followed up via 
electronic pharmacy and medical records for up to 33 
more months. The follow-up period was divided into 
3-month intervals; patients were considered adherent if 
statin therapy was available > or =80% of the time. A 
generalized linear model for repeated measures 
quantified the association between change in LDL 
cholesterol at 4-12 weeks and medication adherence in 
subsequent intervals, adjusting for demographic, 
clinical, and health-service-use variables. 
 9,510  The final sample consisted of 9510 patients. 
Medication adherence decreased significantly 
over time: 59%, 40%, 34%, and 21% of patients 
were adherent at 3, 6, 12, and 36 months, 
respectively. Mean +/- S.D. LDL cholesterol 
reduction at 12 weeks was 28.9% +/- 19.9%. 
The relative LDL cholesterol reduction at 12 
weeks was significantly and independently 
associated with subsequent medication 
adherence: Compared with subjects in the first 
quartile of LDL cholesterol reduction, those in 
quartiles 2, 3, and 4 were more likely to be 
adherent in any subsequent interval (adjusted 
odds ratio [95% confidence interval], 1.26 
[1.12-1.42], 1.25 [1.11-1.40], and 1.15 [1.02-
1.29], respectively). Other independent 
predictors of adherence in months 4-36 
included adherence during the initial three 





Greater reduction in LDL 
cholesterol levels during 
the first three months of 
statin therapy was 
associated with greater 
adherence to lipid-
lowering drug therapy. 
 
Wenger NK, Lewis SJ, Herrington 
DM, Bittner V, Welty FK. Outcomes 
of using high- or low-dose atorvastatin 
in patients 65 years of age or older 
with stable coronary heart disease. 
Annals of internal medicine. 2007 Jul 
3;147(1):1-9. PubMed PMID: 
17606955. Epub 2007/07/04. eng. 
A prespecified secondary analysis of the Treating to 




(256 sites in 14 
countries 
participating in 




The analysis suggests that additional clinical 
benefit can be achieved by treating older 
patients with CHD more aggressively to reduce 
low-density lipoprotein cholesterol levels to less 
than 2.6 mmol/L (<100 mg/dL). The findings 
support the use of intensive low-density 
lipoprotein cholesterol-lowering therapy in 
high-risk older persons with established 
cardiovascular disease. Click here for related 
information on atorvastatin 
No yes   
Pedersen TR, Faergeman O, Kastelein 
JJP, Olsson AG, Tikkanen MJ, Holme 
I, et al. High-Dose Atorvastatin vs 
Usual-Dose Simvastatin for Secondary 
Prevention After Myocardial 
InfarctionThe IDEAL Study: A 
Randomized Controlled Trial. JAMA. 
2005;294(19):2437-45. 
A prospective, randomized, open-label, blinded end-
point evaluation trial.  
 
8888 In this study of patients with previous MI, 
intensive lowering of LDL-C did not result in a 
significant reduction in the primary outcome of 
major coronary events, but did reduce the risk 
of other composite secondary end points and 
nonfatal acute MI. There were no differences in 
cardiovascular or all-cause mortality.  
No Yes  Patients with MI may 
benefit from intensive 
lowering of LDL-C 
without an increase in 
noncardiovascular 





















Cannon CP, Braunwald E, McCabe 
CH, Rader DJ, Rouleau JL, Belder R, 
et al. Intensive versus moderate lipid 
lowering with statins after acute 
coronary syndromes. The New 
England journal of medicine. 2004 
Apr 8;350(15):1495-504. PubMed 
PMID: 15007110. Epub 2004/03/10. 
eng. 
A comparison study between 40 mg of 
pravastatin daily dosing (standard 
therapy) and 80 mg of atorvastatin daily 
dosing (intensive therapy). 
The primary end point was a composite 
of death from any cause, myocardial 
infarction, documented unstable angina 
requiring rehospitalization, 
revascularization (performed at least 30 
days after randomization), and stroke. 
The study was designed to establish the 
noninferiority of pravastatin as compared 
with atorvastatin with respect to the time 
to an end-point event. Follow-up lasted 




The median LDL cholesterol level 
achieved during treatment was 95 mg per 
deciliter (2.46 mmol per liter) in the 
standard-dose pravastatin group and 62 
mg per deciliter (1.60 mmol per liter) in 
the high-dose atorvastatin group 
(P<0.001). Kaplan–Meier estimates of 
the rates of the primary end point at two 
years were 26.3 percent in the pravastatin 
group and 22.4 percent in the atorvastatin 
group, reflecting a 16 percent reduction 
in the hazard ratio in favor of atorvastatin 
(P=0.005; 95 percent confidence interval, 
5 to 26 percent). The study did not meet 
the prespecified criterion for equivalence 
but did identify the superiority of the 
more intensive regimen. 
No Yes Among patients who have recently had an 
acute coronary syndrome, an intensive 
lipid-lowering statin regimen provides 
greater protection against death or major 
cardiovascular events than does a standard 
regimen. These findings indicate that such 
patients benefit from early and continued 
lowering of LDL cholesterol to levels 
substantially below current target levels. 
Schwartz GG, Olsson AG, Ezekowitz 
MD, Ganz P, Oliver MF, Waters D, et 
al. Effects of atorvastatin on early 
recurrent ischemic events in acute 
coronary syndromes: the MIRACL 
study: a randomized controlled trial. 
JAMA. 2001 Apr 4;285(13):1711-8. 
PubMed PMID: 11277825. Epub 
2001/04/13. eng. 
A randomized, double-blind trial 
conducted from May 1997 to September 
1999, with follow-up through 16 weeks 
at 122 clinical centers in Europe, North 
America, South Africa, and Australasia. 
 
 
3086 adults. For patients with acute coronary 
syndrome, lipid-lowering therapy with 
atorvastatin, 80 mg/d, reduces recurrent 
ischemic events in the first 16 weeks, 
mostly recurrent symptomatic ischemia 
requiring rehospitalization 
No Yes  
Olsson AG, Schwartz GG, Szarek M, 
Luo D, Jamieson MJ. Effects of high-
dose atorvastatin in patients > or =65 
years of age with acute coronary 
syndrome (from the myocardial 
ischemia reduction with aggressive 
cholesterol lowering [MIRACL] 
study). The American journal of 
cardiology. 2007 Mar 1;99(5):632-5. 
PubMed PMID: 17317362. Epub 
2007/02/24. eng. 
The MIRACL study randomized patients 
to 16 weeks of 80 mg/day of atorvastatin 
or placebo 24 to 96 hours after ACS.  
This post hoc analysis compared benefits 
of 80 mg of atorvastatin in older (> or 




Event rates were approximately two- to 
threefold higher in older than in younger 
patients. Treatment-by-age heterogeneity 
testing indicated no difference in 
treatment effect by age for any of the 
primary or secondary end points, and 
relative risk decreases in the primary end 
point with atorvastatin versus placebo 
were similar in younger and older 
patients (22% vs 14%, respectively). The 
safety profile of atorvastatin was similar 
between the 2 age groups.  
No Yes These results and a greater immediate 
cardiovascular risk in older patients argue 
for early, intensive atorvastatin therapy as 

















Gibson DM, Bron NJ, Richens MA, 
Hounslow NJ, Sedman AJ, Whitfield 
LR. Effect of Age and Gender on 
Pharmacokinetics of Atorvastatin in 
Humans. The Journal of Clinical 
Pharmacology. 1996;36(3):242-6. 
The effects of age and 
gender on the 
pharmacokinetics of 
atorvastatin after 
administration of single 20-
mg tablets of atorvastatin 
were studied 
32 The equivalent maximum concentration of 
atorvastatin was 42.5% higher in elderly participants 
than in young participants and 17.6% higher in 
women than in men. The mean area under the 
concentration-time curve and half-life were 27.3% 
greater and 36.2% longer, respectively, in elderly 
adults than in young adults and 11.3% lower and 
19.9% shorter, respectively, in women than in men. 
Yes Yes Results of subsequent safety 
and efficacy trials should help 
clarify the clinical significance 
of these pharmacokinetic 
differences. 
Rosuvastatin 
Ridker PM, Danielson E, Fonseca FA, 
Genest J, Gotto AM, Jr., Kastelein JJ, et 
al. Rosuvastatin to prevent vascular 
events in men and women with elevated 
C-reactive protein. The New England 
journal of medicine. 2008 Nov 
20;359(21):2195-207. PubMed PMID: 
18997196. Epub 2008/11/11. eng. 
a randomized, double-blind, 
placebo-controlled, 
multicenter trial_ 
Subjects were  randomly 
assigned to rosuvastatin, 20 
mg daily, or placebo and 
followed them for the 
occurrence of the combined 




hospitalization for unstable 




In this trial of apparently healthy persons without 
hyperlipidemia but with elevated high-sensitivity C-
reactive protein levels, rosuvastatin significantly 
reduced the incidence of major cardiovascular events.  
No Yes   
Glynn RJ, Koenig W, Nordestgaard BG, 
Shepherd J, Ridker PM. Rosuvastatin 
for primary prevention in older persons 
with elevated C-reactive protein and low 
to average low-density lipoprotein 
cholesterol levels: exploratory analysis 
of a randomized trial. Annals of internal 
medicine. 2010 Apr 20;152(8):488-96, 
W174. PubMed PMID: 20404379. 
Pubmed Central PMCID: PMC2946369. 
Epub 2010/04/21. eng. 
a randomized, double-blind, 
placebo-controlled trial. 
, Participants were randomly 
assigned in a 1:1 ratio to 
receive 20 mg of 
rosuvastatin daily or 
placebo. 
5695 were 
70 years or 
older. 
 
In apparently healthy older persons without 
hyperlipidemia but with elevated high-sensitivity C-
reactive protein levels, rosuvastatin reduces the 
incidence of major cardiovascular events. 

















Mora S, Ridker PM. Justification for the 
Use of Statins in Primary Prevention: an 
Intervention Trial Evaluating Rosuvastatin 
(JUPITER)--can C-reactive protein be 
used to target statin therapy in primary 
prevention? The American journal of 
cardiology. 2006 Jan 16;97(2A):33A-41A. 





 The most important action of 3-hydroxy-3-methylglutaryl coenzyme 
A reductase inhibitors (statins) is their ability to lower levels of low-
density lipoprotein (LDL) cholesterol. Statins have proved highly 
effective in reducing the risk of cardiovascular events in both 
primary and secondary prevention studies. However, the magnitude 
of risk reduction associated with statins is greater than that predicted 
on the basis of LDL cholesterol lowering alone. A likely explanation 
for this effect is the anti-inflammatory action of statins. Following 
the observation that high-sensitivity C-reactive protein (hs-CRP) is a 
powerful predictor of cardiovascular events, investigators in the 
Cholesterol and Recurrent Events (CARE) and Air Force/Texas 
Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) 
trials demonstrated that the magnitude of risk reduction associated 
with statin therapy was higher among those with elevated hs-CRP 
levels. In addition, there is accumulating evidence that statins lower 
plasma levels of hs-CRP in a manner largely independent of LDL 
cholesterol lowering. In contrast, little benefit has been demonstrated 
for statin therapy in the absence of both hyperlipidemia and 
inflammation. Justification for the Use of Statins in Primary 
Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) is a large multinational, long-term, double-blind, 
placebo-controlled, randomized clinical trial designed to assess 
directly whether statin therapy (rosuvastatin 20 mg/day) should be 
given to apparently healthy individuals with low LDL cholesterol 
levels but elevated hs-CRP levels--a critical issue for the prevention 
of cardiovascular disease. Support for the concept behind the 
JUPITER trial is also now available from several recent trials 
comparing different intensities of statin therapy on disease 
progression as well as clinical end points. These studies indicate that 
the hs-CRP level achieved after initiation of statin therapy may be as 
important as the LDL cholesterol level achieved. All of these data 
raise the possibility that hs-CRP could be used to target high-risk 
patients who may benefit from early statin use. Ongoing work will 
determine whether hs-CRP reduction, independent of LDL 
cholesterol reduction, results in a net clinical benefit 
- Yes  
Narla V, Blaha MJ, Blumenthal RS, 
Michos ED. The JUPITER and AURORA 
clinical trials for rosuvastatin in special 
primary prevention populations: 
perspectives, outcomes, and consequences. 
Vascular health and risk management. 
2009;5:1033-42. PubMed PMID: 
20057896. Pubmed Central PMCID: 
PMC2801627. Epub 2010/01/09. eng. 
This review outlines the 
JUPITER and AURORA 
trials, interprets the data and 
significance of the results, 
analyses the drawbacks and 
impact of both trials and 
delineates the potential for 
further clinical trials. 
 
  No Yes  
Ridker PM, Glynn RJ. The JUPITER 
Trial: responding to the critics. The 
American journal of cardiology. 2010 Nov 
1;106(9):1351-6. PubMed PMID: 
21029837. Epub 2010/10/30. eng. 
Responding to the critics of 
the JUPITER Trial 
  No Yes  
 






Neutel JM, Weber MA, Julius S, Cohn 
JN, Turlapaty P, Shen Y, et al. Clinical 
experience with perindopril in elderly 
hypertensive patients: a subgroup 
analysis of a large community trial. 
American journal of cardiovascular 
drugs : drugs, devices, and other 
interventions. 2004;4(5):335-41. 
PubMed PMID: 15449975. Epub 
2004/09/29. eng. 
participantsreceived open-label 
perindopril 4 mg once a day for 6 weeks. 
After 6 weeks the dosage was either 
maintained (group I) or increased to 8 
mg/day (group II) based on the 
physician's assessment of blood pressure 
(BP) response. Patients were then 
followed for another 6 weeks for a total 






Demographic and baseline clinical characteristics 
revealed a higher proportion of women, longer duration of 
hypertension and higher baseline systolic BP (SBP) 
among elderly than young (<65 years, n = 7332) 
hypertensive patients. A clinically relevant BP reduction 
of similar magnitude was obtained in elderly and young 
patients with perindopril monotherapy. At week 12, the 
mean reduction in BP from baseline was 18.4/8.7 mm Hg 
in the elderly and 17.5/11.3 mm Hg in the young. Elderly 
patients with hypertension not responding adequately to 
the 4 mg/day dosage at week 6 had a BP reduction of 
6.3/3.6 mm Hg (group II). Up-titration to an 8 mg/day 
dosage for another 6 weeks gave an additional 8.9/3.5 mm 
Hg reduction resulting in a total reduction of 15.2/7.1 mm 
Hg from baseline. A similar magnitude of increase in 
response to up-titration of perindopril was seen in young 
patients. BP control (<140/90 mm Hg) on perindopril 
monotherapy was achieved in 41.4% of elderly and 51.9% 
of young patients. In both age groups, up-titration to an 
8.0 mg/day dosage in group II patients increased BP 
control by approximately 5-fold at week 12 (28.2% in the 
elderly and 36.4% in the young). A similar increased 
response on BP reduction and BP control (<140/90 mm 
Hg) with up-titration was seen in elderly subgroups of 
African American and diabetic patients. The 7th Report of 
the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure 
recommended target goal of <130/80 mm Hg was 
achieved with perindopril monotherapy in 15.6% of 
hypertensive diabetic patients. Perindopril reduced BP 
effectively and safely in very elderly (> or =75 years) 
hypertensive patients. Perindopril was well tolerated in 
elderly patients including high-risk groups. The incidence 
of cough (7-10%), the most common symptom, was 
similar in all age groups. The low incidence of postural 
hypotension (< or =0.2%) observed in the elderly and 
very elderly further supports the good tolerance and safety 
profile of the drug. Data analysis from this study suggests 
that community physicians, in general, are less aggressive 
in controlling BP in the elderly and more inclined to treat 
or control diastolic BP than SBP. 
 
No yes  Perindopril 
treatment is 
effective and well 



















Ferrari R. Effects of angiotensin-
converting enzyme inhibition with 
perindopril on left ventricular 
remodeling and clinical outcome: 
results of the randomized Perindopril 
and Remodeling in Elderly with Acute 
Myocardial Infarction (PREAMI) 
Study. Archives of internal medicine. 
2006 Mar 27;166(6):659-66. PubMed 
PMID: 16567606. Epub 2006/03/29. 
eng. 
Double-blind, randomized, parallel-
group, multicenter, placebo-controlled 
study. Participants were randomized to 
receive perindopril erbumine or 
placebo (8 mg/d) for 12 months.  
1252 The primary end point (death, hospitalization for 
heart failure, or left ventricular remodeling) 
occurred in 181 patients (35%) taking perindopril 
and 290 patients (57%) taking placebo, with a 
significant absolute risk reduction of 0.22 (95% 
confidence interval, 0.16 to 0.28; P<.001). A total 
of 126 patients (28%) and 226 patients (51%) in 
the perindopril and placebo groups, respectively, 
experienced remodeling. The mean increase in 
left ventricle end-diastolic volume was 0.7 mL 
with perindopril compared with 4.0 mL with 
placebo (P<.001). In the perindopril group, 40 
deaths (6%) and 22 hospitalizations (4%) for heart 
failure occurred, whereas 37 deaths (6%) and 30 
hospitalizations (5%) occurred in the placebo 
group. Treatment did not affect death, whereas the 
hospitalization rate for heart failure was slightly 
reduced (absolute risk reduction, 0.01; 95% 
confidence interval, -0.01 to 0.02). No treatment 
effect on other secondary end points 
(cardiovascular death, hospitalization for 
reinfarction or angina, and revascularization) was 
detected.  
No Yes  One year treatment with 
8 mg/d of perindopril 
reduces progressive left 
ventricular remodeling 
that can occur even in 
the presence of small 
infarct size, but it was 
not associated with 
better clinical outcomes. 
Lees KR, Green ST, Reid JL. Influence 
of age on the pharmacokinetics and 
pharmacodynamics of perindopril. 
Clinical Pharmacology & Therapeutics. 
1988;44(4):418-25. 
double-blind, crossover, acute study 16 Mild headache and light-headedness were the 
only adverse effects and were more common in 
the younger subjects. Blood pressure fall was 
greater in the elderly even after correction for 
starting blood pressure. Bioavailability of S-9780 
was increased in the mainly because of increased 
conversion rather than absorption. Renal 
clearance of S-9780 was lower in the elderly  
Yes Yes Dose reduction of 
approximately 50% is 
suggested for elderly 
patients with further 
adjustment proportional 






















Abernethy DR, Gutkowska J, 
Lambert MD. Amlodipine in 
elderly hypertensive patients: 
pharmacokinetics and 
pharmacodynamics. Journal of 
cardiovascular pharmacology. 
1988;12 Suppl 7:S67-71. 
PubMed PMID: 2467133. 
Epub 1988/01/01. eng. 
Participantsreceived amlodipine by i.v. 
infusion (2.5, 5.0, or 10.0 mg). Patients 
were then started on oral amlodipine 2.5 
mg daily for 2 weeks, at the end of 
which amlodipine disposition and effect 
were evaluated over one 24-h dose 
interval. Patients were treated 
subsequently with amlodipine in an 
escalating dose protocol (maximum 
10.0 mg once daily) for 12 weeks to 
control blood pressure.  
14  After i.v. amlodipine, clearance tended to be decreased 
in elderly as compared with young patients with resulting 
prolongation in elimination half-life (64± 20 vs. 48 ± 8 h; 
mean ± SD). Maximum decrease in systolic blood pressure 
(SBP) after i.v. doses tended to be greater in the elderly (-34 
± 15 vs. -23 ± 15 mm Hg) and maximum decrease in 
diastolic blood pressure (DBP) was similar in the two 
groups (− 21 ± 10 vs. - 18 ± 7 mm Hg). SBP was 
significantly decreased after 14 weeks' therapy in 
the elderly at doses ranging from 2.5 to 10.0 mg per day 
(171 ± 17 to 149 ± 22 mm Hg; p < 0.01). DPB was 
decreased both at 2 and 14 weeks' therapy in 
the elderly(baseline 100 ± 7, 2 weeks 93 ± 5, 14 weeks 90 ± 
5 mm Hg; p < 0.01 vs. baseline). Similar decreases in DBP 
were noted in young patients (baseline 96 ± 6, 2 weeks 81 ± 
15, 14 weeks 84 ± 15 mm Hg). Humoral measures at 
baseline (pretreatment), 2 weeks' therapy, and 14 weeks' 
therapy were as follows: norepinephrine (640, 498, 454 
pg/ml; NS), epinephrine (70, 59, 60 pg/ml; NS), plasma 
renin activity (1.5, 1.8, 2.0 ng ml−1h−1; NS), urinary 
aldosterone excretion rate (11.4, 13.4, 11.0 μg/24 h; NS), 
and plasma atrial natriuretic factor (71.1, 80.4, 68.3 pg/ml; 
NS). Amlodipine clearance tends to be decreased 
in elderly patients, suggesting increased drug accumulation 
during chronic dosing. No obvious drug-related side effects 
were noted in any patient. 
No Yes  Amlodipine is effective as 
single-drug therapy in the 
treatment of both systolic and 
diastolic hypertension in 
the elderly and diastolic 
hypertension in younger patients. 
Pascual J. Hypertension 
control in the elderly with 
amlodipine. Current medical 
research and opinion. 
2000;16(1):33-6. PubMed 
PMID: 16422032. Epub 
2006/01/21. eng. 
Research article   Treatment of hypertension in the elderly reduces the 
incidence of cardiovascular events. Some classes of 
antihypertensive drugs, including long-acting 
dihydropyridine calcium channel blockers such as 
amlodipine, can be prescribed in the presence of comorbid 
conditions. The results of clinical trials support the use of 
long-acting dihydropyridine calcium channel blockers in the 
elderly; 
- Yes Amlodipine has been shown to 
be effective and well tolerated in 
the elderly population. 
Abernethy DR. Amlodipine: 
pharmacokinetic profile of a 
low-clearance calcium 
antagonist. Journal of 
cardiovascular pharmacology. 
1991 1991;17 Suppl 1:S4-7. 
PubMed PMID: 16296697. 
eng. 
  Amlodipine is absorbed gradually after oral administration 
(peak plasma levels 6-12 h postdose) and has an absolute 
bioavailability of 64%. Low clearance and a high volume of 
distribution give amlodipine a long elimination half-life, 
and mean effective plasma levels are maintained with once-
daily doses. With repeated once-daily dosing, the steady 
state is achieved after the seventh to ninth dose. The 
pharmacokinetic properties of amlodipine avoid the sharp 
fluctuations in plasma level seen with other calcium 
antagonists that are associated with vasodilatation-induced 
side effects such as tachycardia, headache, and flushing. 
Yes Yes The pharmacokinetics of 
amlodipine are not significantly 
altered in elderly or renally 
impaired patients, but there is 
reduced clearance in patients 
with hepatic impairment. There 
are no pharmacokinetic 
interactions between amlodipine 




















- - Amlodipine is a low-clearance, 
dihydropyridine calcium antagonist. The 
slow rate of elimination (elimination half-
life of 40-60 h) confers several 
pharmacokinetic characteristics that are not 
seen with other calcium-antagonist drugs.It 
has high oral bioavailability (60-80%) and 
accumulates to a steady-state with once-
daily administration over a period of 1-1 ½ 
weeks. 
Yes - Amlodipine is a low-clearance, 
dihydropyridine calcium antagonist 
which is effective for the treatment of 
hypertension and angina pectoris with 
once-daily dosing. 
Paracetamol  
Mian P, Allegaert K, Spriet I, 
Tibboel D, Petrovic M. 
Paracetamol in Older People: 
Towards Evidence-Based 
Dosing? Drugs & aging. 
2018;35(7):603-24. PubMed 
PMID: 29916138. Epub 06/19. 
eng. 
 A search was performed to 
retrieve studies on paracetamol 
pharmacokinetics and safety in 
older people or studies that 
performed a sub-analysis of 
pharmacokinetics and safety in 




and studied  
Differences in paracetamol CL 
and Vd between young and robust older 
people have been reported, with an even 
further decrease in those pharmacokinetics 
parameters in frail older people. Based on 
the—albeit limited—observations retrieved 
in our search, there is no evidence that 
supports a higher incidence of 
hepatotoxicity in paracetamol at normal 
dosages in older subjects. Overall, due to 
limited and heterogeneous evidence, it was 
difficult to drawn firm and meaningful 
conclusions on changed risk for 
paracetamol safety in older people. 
Yes 
 
Yes Population pharmacokinetics 
modelling can be considered a 
valuable tool to develop more 
evidence-based dosing advice for older 
people. In addition, more clinical 
studies with enriched clinical 
characteristics (e.g. comorbidity, 
comedication, frailty) should be 
conducted to study both the 
pharmacokinetics of paracetamol (and 
its metabolites) and its safety 
parameters. 
Fulton B, James O, Rawlins 
MD. The influence of age on 
the pharmacokinetics of 
paracetamol [proceedings]. 
British journal of clinical 
pharmacology. 1979 
Apr;7(4):418P. PubMed 
PMID: 444368. Epub 
1979/04/01. eng. 
Each individual received both 
oral (500mg Panadol)and 
intravenous (500mg) paracetamol 
on separate occasion one week 
apart. None was receiving any 
drug known to induce hepatic 
microsomal oxidation and all had 
normal biochemical indices of 
hepatic and renal function.  
Venous blood was sampled over 
6 h following drug administration 
and plasma concentration 
determined by gas 
chromatography. 
A two compartment open model 
was used in the analysis of the 
data. 
 
23  In the elderly, Plasma paracetamol 
clearance and  the volume of central 
compartment were significantly reduced as 
compared with the young. Bioavailability 
was similar in the two groups. 
Yes  Yes  The results suggest that although 
bioavailability of paracetamol is 
normal in the elderly, paracetamol 













Wynne HA, Cope LH, Herd B, Rawlins MD, 
James OF, Woodhouse KW. The association 
of age and frailty with paracetamol 
conjugation in man. Age and ageing. 1990 
Nov;19(6):419-24. PubMed PMID: 2285011. 
Epub 1990/11/01. eng. 
The association of age, physical 
frailty and liver size upon hepatic 
conjugation reactions was studied 
using paracetamol as a model drug.  
47 Paracetamol clearance expressed in terms of 
body weight was significantly lower in the 
fit elderly than in the fit young subjects, and 
was lowest in the frail elderly subjects (p 
less than 0.01). There was no difference in 
paracetamol clearance expressed per unit 
volume of liver between the fit young and 
fit elderly subjects but it was significantly 
reduced in the frail subjects. Although the 
partial metabolic clearance to paracetamol 
sulphate was preserved per unit volume of 
liver with ageing and frailty, the partial 
metabolic clearance to paracetamol 
glucuronide per unit volume of liver was 
markedly reduced in the frail elderly (p less 
than 0.01) when compared with the fit 
subjects. 
Yes Yes These results show that age-
associated changes in 
paracetamol clearance are 
attributable to both changes 
in liver volume and in 
general health. The findings 
underline the important 
influences of the elderly 
person's physical state upon 
drug clearance. 
Bedjaoui A, Demotes-Mainard F, Raynal F, 
Vincon G, Galley P, Albin H. [Effect of age 
and sex on the pharmacokinetics of 
paracetamol]. Therapie. 1984 Jul-
Aug;39(4):353-9. PubMed PMID: 6484879. 
Epub 1984/07/01. Influence de l'age et du sexe 
sur la pharmacocinetique du paracetamol. fre. 
   Yes Yes  
Mitchell SJ, Hilmer SN, Murnion BP, 
Matthews S. Hepatotoxicity of therapeutic 
short-course paracetamol in hospital inpatients: 
impact of ageing and frailty. Journal of clinical 
pharmacy and therapeutics. 2011 
Jun;36(3):327-35. PubMed PMID: 21545612. 
Epub 2011/05/07. eng. 
An observational cohort study. 
Treatment group participants 
commenced regular paracetamol (3-4 
g/day) during their hospital admission, 
whereas the control group was not 
exposed to paracetamol. In both 
groups, plasma alanine 
aminotransferase (ALT) was 
measured at baseline and day 5, and 
risk factors for raised ALT were 
recorded. A random serum 
paracetamol concentration was 
measured at day 5 in the treatment 
group. 
 
 No older frail treatment participants had an 
abnormal day 5 ALT. Odds ratios for having 
a day 5 ALT above the upper limit of normal 
(ULN) with paracetamol use, compared with 
unexposed controls, were 3·7 [95% 
confidence intervals (CI): 0·32, 41·59] for 
older not frail participants and 2·5 (95% CI: 
0·34, 18·3) for younger participants. 
Decreasing frailty score independently 
predicted a day 5 ALT above the ULN (P < 
0·05). Day 5 serum paracetamol 
concentrations were highest in older frail 
participants (P < 0·005). 
 
Yes yes  
Higher paracetamol 
concentrations observed in 
frail older patients after 5 
days of therapeutic 
paracetamol do not 
necessarily indicate an 
















Koppert W, Frotsch K, Huzurudin N, 
Boswald W, Griessinger N, Weisbach 
V, et al. The effects of paracetamol and 
parecoxib on kidney function in elderly 
patients undergoing orthopedic surgery. 
Anesthesia and analgesia. 2006 
Nov;103(5):1170-6. PubMed PMID: 
17056950. Epub 2006/10/24. eng. 
The study determine the effects of IV 
paracetamol or parecoxib on renal 
function in elderly patients undergoing 
orthopedic surgery. this is a 
randomized and placebo-controlled 
study. After their arrival in the 
postanesthesia care unit, patients 
received an initial dose of the study 
medication, paracetamol 1000 mg IV 
(n = 25), parecoxib 40 mg IV (n = 25), 
or saline IV (n = 25); subsequent doses 
were administered for the next 3 days. 
Opioids were provided as rescue 
medication. Blood and urine samples 
were collected before and after 
surgery, and markers of renal function 
were determined.  
75 During the first 2 h after the initial dose 
of parecoxib, creatinine clearance was 
slightly diminished (125 +/- 83 to 86 +/- 
45 mL/min, P < 0.05), whereas no 
significant decrease of creatinine 
clearance was observed in the placebo 
and paracetamol groups. After all 
treatments, sodium and potassium 
excretion as well as urine albumin and 
alpha-1-microglobulin were transiently 
increased (group differences: not 
signicifant). In conclusion, glomerular 
and tubular functions were transiently 
affected in all patients after orthopedic 
surgery; however, the differences 
between the treatment groups were small 
and not clinically relevant. 
Yes Yes Further studies are warranted to 
determine adverse renal effects 
of longer-lasting therapy with 
these drugs, especially in 
patients with renal impairment 
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